Ariad Pharmaceuticals (ARIA) 5.89 $ARIA
Nasdaq stocks posting largest percentage increases
AP - Thu Jul 24, 5:23PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Most active Nasdaq-traded stocks
AP - Thu Jul 24, 5:23PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
3 Huge Stocks to Trade (or Not)
at The Street - Thu Jul 24, 2:09PM CDT
Here's how to trade some of the most active stocks on the market today.
Ariad Pharmaceuticals (ARIA) Worth Watching: Stock Gains 15.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:25AM CDT
Ariad Pharmaceuticals (ARIA) was a big mover last session, with shares rising over 15% on the day.
'Fast Money' Recap: Facebook and Analysts' Expectations
at The Street - Thu Jul 24, 4:00AM CDT
The trading panel discussed why they like Facebook's earnings and why they'd avoid Cheesecake Factory.
Ariad Pharmaceuticals Rises 15.29% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Jul 23, 4:36PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $5.12 to a high of $5.94. Yesterday, the shares gained 15.3%, which took the trading range above the 3-day high of $5.31 on volume of 24.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Ariad Pharmaceuticals Down 13.1% Since SmarTrend Downtrend Call (ARIA)
Comtex SmarTrend(R) - Wed Jul 23, 9:19AM CDT
SmarTrend identified a Downtrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 8th, 2014 at $6.07. In approximately 2 weeks, Ariad Pharmaceuticals has returned 13.11% as of today's recent price of $5.27.
Yellen, Icahn Comments Put a Lid on Small-Cap Stocks, May Hurt Larger Market
at The Street - Wed Jul 16, 10:40AM CDT
Recent comments by Fed Chair Janet Yellen and activist investor Carl Icahn have led to selling pressure in small-cap stocks.
ARIAD to Webcast Conference Call on Second Quarter 2014 Financial Results
Business Wire - Wed Jul 16, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its second quarter 2014 financial results on Wednesday, August 6, 2014, before the market opens. Following the announcement, at 8:30 a.m. Eastern Time, company management will host a conference call and webcast discussion of the results and provide a general corporate update.
Ariad Stock's Biggest Risk Is Its Only Hope
Brian Wilson, The Motley Fool - Motley Fool - Tue Jul 15, 4:00PM CDT
Overreliance on its blood cancer drug Iclusig (ponatinib) continues to make Ariad Pharmaceuticals an incredibly risky biotech play, despite the mature company's relatively low market cap of $1.1 billion. After a dramatic FDA recall in 2013 based...
Stock Market Today: Social Media, Biotech Suffer as Janet Yellen Shares Concerns on Valuation
at The Street - Tue Jul 15, 3:19PM CDT
Major indices trembled and the Nasdaq slid Tuesday following Fed Chair Janet Yellen's remarks on biotech and social media valuations.
ARIAD Announces Continuation of Iclusig Review under the Article 20 Procedure in Europe
Business Wire - Mon Jul 14, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has provided the Company with a request for limited additional information regarding Iclusig(R) (ponatinib) as part of its ongoing review under the Article 20 referral procedure. The PRAC has requested further information regarding proposed dose modifications after achievement of a response and patient monitoring and details concerning a risk management plan. Following ARIAD's response and input from the agency's Scientific Advisory Group, the Company expects that the PRAC will complete its review and make final recommendations to the Committee for Medicinal Products for Human Use (CHMP) at its meeting in October 2014.
ARIAD Pharmaceuticals (ARIA) Is Water-Logged And Getting Wetter Today
at The Street - Tue Jul 08, 9:39AM CDT
Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
UCB, Dermira Sign Cimzia Dermatology Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 5:10PM CDT
UCB SA (UCBJF) and Dermira have entered into a licensing agreement for the development and commercialization of Cimzia in dermatology.
OncoGenex's Apatorsen in Phase II for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 3:30PM CDT
OncoGenex Pharmaceuticals, Inc. (OGXI) announced that apatorsen is in phase II study (Cedar) for advanced squamous cell lung cancer.
Why A Short Covering Rally Might Come for Ariad Pharmaceuticals (ARIA) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 7:42AM CDT
Why A Short Covering Rally Might Come for Ariad Pharmaceuticals (ARIA) Stock
Alcobra (ADHD) Jumps: Stock Adds 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 8:46AM CDT
Alcobra (ADHD) was a big mover last session, with shares rising nearly 6% on the day.
Zogenix, Inc. (ZGNX) Soars: Stock Adds 18.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 7:51AM CDT
Zogenix, Inc. (ZGNX) was a big mover last session, as its shares rose nearly 19% on the day.
Amgen Gets Breakthrough Therapy Status for Leukemia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 4:55PM CDT
Amgen (AMGN) announced that the FDA has granted Breakthrough Therapy Designation to its experimental oncology drug, blinatumomab.
Nasdaq stocks posting largest percentage increases
AP - Thu Jul 24, 5:23PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Most active Nasdaq-traded stocks
AP - Thu Jul 24, 5:23PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
3 Huge Stocks to Trade (or Not)
at The Street - Thu Jul 24, 2:09PM CDT
Here's how to trade some of the most active stocks on the market today.
Ariad Pharmaceuticals (ARIA) Worth Watching: Stock Gains 15.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:25AM CDT
Ariad Pharmaceuticals (ARIA) was a big mover last session, with shares rising over 15% on the day.
'Fast Money' Recap: Facebook and Analysts' Expectations
at The Street - Thu Jul 24, 4:00AM CDT
The trading panel discussed why they like Facebook's earnings and why they'd avoid Cheesecake Factory.
Ariad Pharmaceuticals Rises 15.29% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Jul 23, 4:36PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $5.12 to a high of $5.94. Yesterday, the shares gained 15.3%, which took the trading range above the 3-day high of $5.31 on volume of 24.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Ariad Pharmaceuticals Down 13.1% Since SmarTrend Downtrend Call (ARIA)
Comtex SmarTrend(R) - Wed Jul 23, 9:19AM CDT
SmarTrend identified a Downtrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 8th, 2014 at $6.07. In approximately 2 weeks, Ariad Pharmaceuticals has returned 13.11% as of today's recent price of $5.27.
Yellen, Icahn Comments Put a Lid on Small-Cap Stocks, May Hurt Larger Market
at The Street - Wed Jul 16, 10:40AM CDT
Recent comments by Fed Chair Janet Yellen and activist investor Carl Icahn have led to selling pressure in small-cap stocks.
ARIAD to Webcast Conference Call on Second Quarter 2014 Financial Results
Business Wire - Wed Jul 16, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its second quarter 2014 financial results on Wednesday, August 6, 2014, before the market opens. Following the announcement, at 8:30 a.m. Eastern Time, company management will host a conference call and webcast discussion of the results and provide a general corporate update.
Ariad Stock's Biggest Risk Is Its Only Hope
Brian Wilson, The Motley Fool - Motley Fool - Tue Jul 15, 4:00PM CDT
Overreliance on its blood cancer drug Iclusig (ponatinib) continues to make Ariad Pharmaceuticals an incredibly risky biotech play, despite the mature company's relatively low market cap of $1.1 billion. After a dramatic FDA recall in 2013 based...
Stock Market Today: Social Media, Biotech Suffer as Janet Yellen Shares Concerns on Valuation
at The Street - Tue Jul 15, 3:19PM CDT
Major indices trembled and the Nasdaq slid Tuesday following Fed Chair Janet Yellen's remarks on biotech and social media valuations.
ARIAD Announces Continuation of Iclusig Review under the Article 20 Procedure in Europe
Business Wire - Mon Jul 14, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has provided the Company with a request for limited additional information regarding Iclusig(R) (ponatinib) as part of its ongoing review under the Article 20 referral procedure. The PRAC has requested further information regarding proposed dose modifications after achievement of a response and patient monitoring and details concerning a risk management plan. Following ARIAD's response and input from the agency's Scientific Advisory Group, the Company expects that the PRAC will complete its review and make final recommendations to the Committee for Medicinal Products for Human Use (CHMP) at its meeting in October 2014.
ARIAD Pharmaceuticals (ARIA) Is Water-Logged And Getting Wetter Today
at The Street - Tue Jul 08, 9:39AM CDT
Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
UCB, Dermira Sign Cimzia Dermatology Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 5:10PM CDT
UCB SA (UCBJF) and Dermira have entered into a licensing agreement for the development and commercialization of Cimzia in dermatology.
OncoGenex's Apatorsen in Phase II for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 3:30PM CDT
OncoGenex Pharmaceuticals, Inc. (OGXI) announced that apatorsen is in phase II study (Cedar) for advanced squamous cell lung cancer.
Why A Short Covering Rally Might Come for Ariad Pharmaceuticals (ARIA) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 7:42AM CDT
Why A Short Covering Rally Might Come for Ariad Pharmaceuticals (ARIA) Stock
Alcobra (ADHD) Jumps: Stock Adds 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 8:46AM CDT
Alcobra (ADHD) was a big mover last session, with shares rising nearly 6% on the day.
Zogenix, Inc. (ZGNX) Soars: Stock Adds 18.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 7:51AM CDT
Zogenix, Inc. (ZGNX) was a big mover last session, as its shares rose nearly 19% on the day.
Amgen Gets Breakthrough Therapy Status for Leukemia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 4:55PM CDT
Amgen (AMGN) announced that the FDA has granted Breakthrough Therapy Designation to its experimental oncology drug, blinatumomab.
